A detailed history of Winton Group LTD transactions in Insmed Inc stock. As of the latest transaction made, Winton Group LTD holds 29,794 shares of INSM stock, worth $1.85 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
29,794
Holding current value
$1.85 Million
% of portfolio
0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$25.72 - $29.94 $766,301 - $892,032
29,794 New
29,794 $808,000
Q4 2022

Feb 14, 2023

SELL
$16.98 - $23.15 $26,607 - $36,276
-1,567 Reduced 11.62%
11,919 $238,000
Q3 2022

Nov 10, 2022

BUY
$20.88 - $28.21 $281,587 - $380,440
13,486 New
13,486 $290,000
Q1 2022

May 11, 2022

SELL
$20.42 - $28.13 $268,257 - $369,543
-13,137 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$25.89 - $33.45 $340,116 - $439,432
13,137 New
13,137 $358,000
Q2 2021

Aug 10, 2021

SELL
$24.17 - $36.01 $262,437 - $390,996
-10,858 Closed
0 $0
Q1 2021

Jul 21, 2021

SELL
$32.28 - $44.3 $270,764 - $371,588
-8,388 Reduced 43.58%
10,858 $370,000
Q4 2020

Feb 12, 2021

SELL
$31.45 - $40.54 $505,307 - $651,356
-16,067 Reduced 45.5%
19,246 $641,000
Q3 2020

Oct 30, 2020

BUY
$26.0 - $34.5 $562,354 - $746,200
21,629 Added 158.06%
35,313 $1.14 Million
Q2 2020

Aug 05, 2020

BUY
$14.11 - $29.42 $193,081 - $402,583
13,684 New
13,684 $377,000
Q3 2018

Nov 02, 2018

SELL
$18.95 - $28.08 $180,669 - $267,714
-9,534 Closed
0 $0
Q2 2018

Aug 20, 2018

SELL
$20.0 - $29.72 $234,440 - $348,377
-11,722 Reduced 55.15%
9,534 $0
Q1 2018

May 21, 2018

BUY
$21.69 - $32.99 $461,042 - $701,235
21,256 New
21,256 $0

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.4B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Winton Group LTD Portfolio

Follow Winton Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.